UBS ASSET MANAGEMENT AMERICAS LLC - NGM BIOPHARMACEUTICALS INC ownership

NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 130 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.07 and the average weighting 1.0%.

Quarter-by-quarter ownership
UBS ASSET MANAGEMENT AMERICAS LLC ownership history of NGM BIOPHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$128,2390.0%31,4310.0%0.00%
Q1 2023$128,239
-18.7%
31,4310.0%0.00%
Q4 2022$157,783
-100.0%
31,431
+2.2%
0.00%
Q3 2022$402,432,000
-9.4%
30,767
-11.2%
0.00%
Q2 2022$444,379,000
+56.4%
34,663
+86.1%
0.00%
Q1 2022$284,093,000
-13.9%
18,6290.0%0.00%
Q4 2021$329,919,000
-37.1%
18,629
-25.3%
0.00%
Q3 2021$524,344,000
+160.9%
24,945
+144.8%
0.00%
Q2 2021$200,967,00010,1910.00%
Other shareholders
NGM BIOPHARMACEUTICALS INC shareholders Q3 2022
NameSharesValueWeighting ↓
Column Group LLC 18,136,735$232,513,00049.48%
Ponoi II Management, LLC 1,298,908$16,652,00045.25%
Ponoi Management, LLC 1,298,908$16,652,00026.29%
Euclidean Capital LLC 746,674$9,572,0008.14%
StepStone Group LP 1,573,357$20,170,0002.16%
First Light Asset Management, LLC 1,135,884$14,562,0001.69%
Lexington Partners L.P. 110,428$1,416,0000.73%
Rubric Capital Management LP 797,588$10,225,0000.54%
Boxer Capital, LLC 500,000$6,410,0000.41%
DAFNA Capital Management LLC 107,653$1,380,0000.38%
View complete list of NGM BIOPHARMACEUTICALS INC shareholders